19 recruiting, 15 completed, 12 unknown, 8 terminated. 33 Phase 2, 14 Phase 3, 4 Phase 1, 3 Not applicable, 1 Phase 4.
Follow Chemoradiation: new trials by email Literature Review of Chemoradiation trials Research Report on Chemoradiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC Enfortumab Vedotin, Pembrolizumab, Radiation - Urothelial Bladder Cancer | Phase 2 | Not yet recruiting | The Netherlands Cancer Institute | 56 | 2026-09-01 | 2026-06-25 |
| Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma Biopsy Procedure, Biospecimen Collection, Carboplatin - Sinonasal Squamous Cell Carcinoma, Stage III Sinonasal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 108 | 2026-09-01 | 2026-10-05 |
| A Clinical Trial to Evaluate the Safety, Tolerability and Clinical Efficacy of M3T01 Monotherapy and in Combination With Pembrolizumab and Other Systemic Therapies M3T01, Pembrolizumab, Chemoradiation - Advanced Solid Tumors | Phase 1 | Recruiting | Providence Health & Services | 110 | 2025-06-17 | 2026-07-23 |
| A Study of Reduced Radiation Therapy With Chemotherapy in People With HPV-Positive Throat Cancer 18F-FMISO PET/CT Scan, Chemoradiation, Questionnaires - Oropharyngeal Carcinoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 74 | 2025-05-13 | 2026-05-11 |
| Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer Cisplatin - Oropharyngeal Cancer, Carcinoma | Phase 2 | Recruiting | Zachary Zumsteg | 50 | 2025-05-12 | 2026-08-05 |
| G-CSF After Chemo-radiation in Patients With Glioblastoma Granulocyte Colony Stimulating Factor (G-CSF), Radiation Therapy + Temozolomide - MGMT-Methylated Glioblastoma, Glioblastoma (GBM) | Phase 2 | Recruiting | Massachusetts General Hospital | 60 | 2025-04-02 | 2026-05-05 |
| Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma Fenofibrate, Cervical Conization, Hysterectomy - Cervical Intraepithelial Neoplasia, Invasive Cervical Cancer | Phase 1 | Recruiting | Lindsay Ferguson, MD | 24 | 2024-11-20 | 2026-07-27 |
| A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer FMISO-PET Scan, Chemoradiation, Assessments - HPV-Related Squamous Cell Carcinoma | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 291 | 2024-08-19 | 2026-09-24 |
| Postoperative Radiotherapy in Breast Cancer- Concurrent or Sequential With Chemotherapy Chemoradiation - Invasive Breast Cancer, Stage III Breast Cancer | Phase 3 | Recruiting | Dr. Tabassum Wadasadawala | 858 | 2024-05-14 | 2025-04-13 |
| Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC Paclitaxel and Carboplatin, Chemoradiation - Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva | Phase 2 | Recruiting | The Netherlands Cancer Institute | 98 | 2024-01-01 | 2024-04-15 |
| Induction Chemotherapy and Tazemetostat for Locally Advanced SMARCB1-deficient Sinonasal Carcinoma Docetaxel, Cis Platinum, 5-FU - Sinonasal Carcinoma | Phase 2 | Not yet recruiting | Dr. Victor H.F. Lee | 30 | 2023-09-01 | 2023-02-28 |
| Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer Neoadjuvant Therapy, CCRT, Brachytherapy - Cervical Cancer | Phase 3 | Recruiting | Sichuan Cancer Hospital and Research Institute | 286 | 2023-07-24 | 2023-12-27 |
| A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze) Surgery, Chemoradiation, Observation - Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 150 | 2023-04-27 | 2026-02-02 |
| Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer Chemoradiation, Pamiparib, Hydroxyurea - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | University of Chicago | 30 | 2023-03-07 | 2026-03-04 |
| A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer mFOLFIRINOX, 5-Fluorouracil (5-FU), Oxaliplatin - Pancreatic Cancer, Resectable Pancreatic Cancer | Phase 2 | Terminated | Kimberly Perez, MD | 8 | 2023-01-06 | 2024-12-17 |
| Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer Nivolumab 40 mg in 4 ml Injection, Ipilimumab 200 MG in 40 ML Injection, Chemoradiation - Uterine Cervical Neoplasms | Phase 2 | Recruiting | Hospital Israelita Albert Einstein | 112 | 2022-08-30 | 2024-01-05 |
| FOLFIRINOX + NIS793 in Pancreatic Cancer FOLFIRINOX, Oxaliplatin, Leucovorin - Pancreas Cancer, Metastatic Pancreatic Cancer | Phase 1 | Terminated | Colin D. Weekes, M.D., PhD | 4 | 2022-08-09 | 2025-11-18 |
| Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Nab-PTX,S-1,Tirelizumab, Chemoradiation - Locally Advanced Gastric Cancer | Phase 2 | Unknown | Zhejiang Cancer Hospital | 33 | 2022-01-01 | 2022-09-06 |
| Neoadjuvant Therapy for Localized Rectal Adenocarcinoma Chemoradiation, short course radiation therapy, mFOLFOX6 - Rectal Adenocarcinoma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2021-08-13 | 2021-11-10 | |
| Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma Chemoradiation - Urinary Bladder Cancer | Unknown | Assiut University | 50 | 2021-04-01 | 2021-03-23 |
Showing 20 of 63. Sign in to see all of them.
Rectal Neoplasms (8) · Esophageal Neoplasms (6) · Uterine Cervical Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Head and Neck Neoplasms (4) · Oropharyngeal Neoplasms (4) · Pancreatic Neoplasms (4) · Breast Neoplasms (3) · Lung Neoplasms (3) · Glioblastoma (2) · Urinary Bladder Neoplasms (2) · Adenocarcinoma (1) · Brain Neoplasms (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1)
Abramson Cancer Center at Penn Medicine (3) · M.D. Anderson Cancer Center (3) · University Medical Center Groningen (3) · Assiut University (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · Polish Colorectal Cancer Study Group (2) · Tata Memorial Hospital (2) · The Netherlands Cancer Institute (2) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Candel Therapeutics, Inc. (1) · Celgene (1) · Chinese Academy of Medical Sciences (1) · Chinese University of Hong Kong (1) · Colin D. Weekes, M.D., PhD (1)
United States (30) · China (9) · Netherlands (6) · France (5) · India (5) · Spain (4) · Austria (3) · Canada (3) · Greece (3) · Italy (3) · Poland (3) · Russia (3) · Belgium (2) · Brazil (2) · Germany (2)
Krzysztof Bujko, Prof. (2) · Nancy Lee, MD (2) · Ahmed Moeen (1) · Ajay Sheshadri (1) · Alejandra Martinez, Dr (1) · Alexander Lin, MD (1) · Alexey Tryakin, MD, PhD (1) · Angus CW Chan, MD (1) · Anne Crijns, MD, PhD (1) · Ari Rosenberg, MD (1) · Bonnie Ky, MD, MSCE (1) · Carlos E. Vargas, M.D. (1) · Charalambos Andreadis, MD (1) · Colin D Weekes, MD, PHD (1)
PMID 11398890, PMID 11886723, PMID 16585222, PMID 21166756, PMID 21444871, PMID 22137164, PMID 23874586, PMID 25624177, PMID 26205955, PMID 26527790, PMID 26884592, PMID 27461255, PMID 31122213, PMID 31192355, PMID 31253621, PMID 31953079, PMID 32611448, PMID 33581976, PMID 33794205, PMID 36821132, PMID 38719277, PMID 39415507, PMID 40844778, PMID 41570275
2018 (2), 2016 (1), 2019 (1), UL1TR001120 (1), UM1CA186712 (1)